Status:

UNKNOWN

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Gastrointestinal Carcinoid Tumor

Islet Cell Tumor

Eligibility:

All Genders

18+ years

Brief Summary

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendo...

Detailed Description

OBJECTIVES: Primary * Test the scale structure, reliability, and validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21) in patients with gastrointestinal-related neuroendocrine...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed neuroendocrine tumor OR characteristic radiological findings of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of the following criteria:
  • Primary disease in gut with liver metastases (with or without hormone secretion)
  • Primary disease in lung with liver or abdominal metastases (with or without hormone secretion)
  • Primary disease in pancreas with or without metastases (with or without hormone secretion)
  • PATIENT CHARACTERISTICS:
  • Any Karnofsky performance status allowed
  • Life expectancy ≥ 3 months
  • Able to understand the questionnaire language
  • Mentally fit to complete questionnaire
  • No psychological, familial, sociological, or geographical condition that would limit study compliance
  • No other concurrent malignancies except basal cell carcinoma of the skin
  • PRIOR CONCURRENT THERAPY:
  • More than 2 months since prior somatostatin analogue or interferon therapy (somatostatin therapy stratum)
  • Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable over the past month
  • More than 6 months since prior radionuclide therapy or systemic chemotherapy (radionuclide or systemic chemotherapy stratum)
  • More than 6 months since prior ablative therapies (ablative therapy stratum)
  • No concurrent participation in other quality of life studies

Exclusion

    Key Trial Info

    Start Date :

    October 1 2006

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    408 Patients enrolled

    Trial Details

    Trial ID

    NCT00454376

    Start Date

    October 1 2006

    Last Update

    October 29 2013

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Aarhus Universitetshospital - Aarhus Sygehus

    Aarhus, Denmark, DK 8000

    2

    Charite - Campus Charite Mitte

    Berlin, Germany, D-10117

    3

    Klinikum der Universitaet Regensburg

    Regensburg, Germany, D-93053

    4

    University Athens Alexandras Hospital

    Athens, Greece, 611